Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia? A double-blind comparison of parenteral D- and L-Arginine by Quyyumi, Arshed A
MYOCARDIAL ISCHEMIA
Does Acute Improvement of Endothelial Dysfunction in Coronary
Artery Disease Improve Myocardial Ischemia?
A Double-Blind Comparison of Parenteral D- and L-Arginine
ARSHED A. QUYYUMI, MD, MRCP, FACC
Bethesda, Maryland
Objectives. Parenteral L-arginine will improve myocardial isch-
emia in patients with obstructive coronary artery disease.
Background. Endothelial dysfunction causes coronary arterial
constriction during stress, and L-arginine improves endothelial
dysfunction.
Methods. Twenty-two patients with stable coronary artery
disease and exercise-induced ST-segment depression underwent
assessment of forearm endothelial function with acetylcholine and
symptom-limited treadmill exercise testing during dextrose 5%
infusion and after double-blind intravenous administration of L-
and D-arginine (5 mg/kg/min) for 20 min.
Results. Forearm blood flow increased with both L- and
D-arginine (33% 6 6% and 38% 6 7%, respectively, p < 0.001).
Acetylcholine-mediated forearm vasodilation also improved with
both L- and D-arginine (p < 0.0001). The magnitude of improve-
ment was similar with both enantiomers and was observed in
patients throughout the range of acetylcholine responses and
cholesterol levels.
Heart rate and blood pressure at rest and during each stage of
exercise and exercise duration remained unchanged with L- and
D-arginine compared to control. Ischemic threshold, measured
either as the rate-pressure product or the duration of exercise at
the onset of 1-mm ST-segment depression during exercise, also
remained unchanged. Serum arginine, insulin and prolactin levels
(p < 0.01) increased with both enantiomers.
Conclusions. Parenteral arginine produces non–stereo-specific
peripheral vasodilation and improves endothelium-dependent va-
sodilation in patients with stable coronary artery disease by
stimulation of insulin-dependent nitric oxide release or by non-
enzymatic nitric oxide generation. Despite enhanced endothelial
function, there was no improvement in myocardial ischemia during
stress with either enantiomer. Whether parenteral arginine will be of
therapeutic benefit in acute coronary syndromes and oral arginine in
myocardial ischemia needs to be studied further.
(J Am Coll Cardiol 1998;32:904–11)
©1998 by the American College of Cardiology
Blood vessel tone is modulated by balanced actions of vaso-
constricting and dilating compounds that are either circulating
or locally synthesized in the vascular wall. Predominance of
vasoconstrictor influences, especially in the presence of ath-
erosclerotic coronary arterial narrowing, leads to further re-
striction of myocardial blood flow and exacerbation of isch-
emia (1). Important vasoconstrictors include catecholamines,
angiotensin II and endothelin, and their action appears to be
counterbalanced by locally generated endothelium-derived va-
sodilators such as nitric oxide (NO), prostacyclin and
endothelium-derived hyperpolarizing factor. Nitric oxide, con-
sidered to be the predominant endothelium-derived relaxing
factor, is constitutively synthesized by the action of a calcium-
calmodulin–sensitive enzyme NO synthase on L-arginine (2).
Nitric oxide diffuses luminally into the blood stream and
inhibits platelet aggregation and adhesion, and penetrates
abluminally into the vascular smooth muscle to cause vasodi-
lation. Nitric oxide activity is impaired in the coronary and
peripheral vasculature of patients with atherosclerosis and
those with risk factors for atherosclerosis (3–8). This abnor-
mality is associated with paradoxical vasoconstriction or failure
of appropriate vasodilation of blood vessels in response to
physiologic stress (9–12) that in turn may exacerbate myocar-
dial ischemia in patients with obstructive coronary artery
disease. Therapies designed to improve NO bioavailability
would therefore be expected to increase vascular dilator tone
at rest and during exercise and thereby ameliorate myocardial
ischemia.
One strategy widely tested in recent years to improve
vascular NO activity is the replenishment of L-arginine, the
substrate for NO synthesis. L-arginine administration im-
proved abnormal endothelium-dependent vasodilation in hy-
percholesterolemia (13–15). Intraarterial L-arginine also im-
proved abnormal endothelium-dependent responses in the
coronary vasculature of patients with atherosclerosis and in-
hibited the abnormal coronary constriction observed with
pacing (16–18). A recent report demonstrated vasodilation of
coronary stenoses with intracoronary L-arginine (19). On the
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basis of these observations, we hypothesized that parenteral
L-arginine, by improving NO bioavailability, will improve
myocardial ischemia in patients with obstructive atheroscle-
rotic coronary artery disease by abrogating coronary constric-
tion during stress.
Methods
Patients. We studied 22 patients, 19 men and 3 women
(mean age 63.5 6 2 years) with stable symptoms, angiographi-
cally documented coronary artery disease and exercise-induced
ST-segment depression. Patients had undergone previous
treadmill exercise testing on at least two or more occasions and
had demonstrable ischemia on radionuclide testing. Mean
serum cholesterol was 243 6 12 mg/dl, seven patients were
hypertensive, six diabetic and four were current smokers or
had smoked in the past year. None had suffered from unstable
angina or myocardial infarction in the 3-month period before
the study, and all patients were free of symptoms of heart
failure. Patients gave informed consent and the protocol was
approved by the Investigational Review Board of the National
Heart, Lung and Blood Institute.
Protocol. On the first day, an intraarterial cannula was
introduced under local anesthesia in the brachial artery of the
nondominant arm. After 1-h rest, dextrose 5% (D5W) was
given intravenously at 2 ml/min and patients were exercised on
the treadmill, employing the National Institutes of Health
Combined protocol (20). Blood pressure, heart rate and a
12-lead electrocardiogram were recorded every 30 s to accu-
rately determine the ischemic threshold (heart rate and blood
pressure at the onset of 1-mm ST-segment depression). Exer-
cise was terminated for moderate intensity chest pain, limiting
dyspnea, $3 mm ST-segment depression, hypertension or
excessive fatigue.
After a 3-h recovery period on day 1, patients had deter-
mination of forearm endothelial function with intraarterial
acetylcholine (ACH). This was followed by a double-blind
randomized intravenous infusion of either L-arginine or
D-arginine (Sigma Chemical) at 5 mg/kg/min for 20 min. In our
preliminary experience, the infusion of 10 mg/kg/min arginine
caused nausea in some patients. After 20 min of arginine
infusion, determination of forearm endothelial function using
intraarterial ACH was repeated. After this and approximately
30 min after commencing arginine infusion, treadmill exercise
testing was performed and the infusion was terminated after
the end of exercise.
The following day, repeat measurement of endothelial
function was performed with intraarterial ACH and these
measurements were repeated 20 min after either intravenous
L-arginine or D-arginine. At the end of these measurements
treadmill exercise testing was repeated while continuing infu-
sion of intravenous arginine, as on the previous day.
Measurement of forearm endothelial function. All studies
were performed in a quiet room with a temperature of
approximately 22°C, as previously described (21,22). Patients
were asked to refrain from drinking alcohol or beverages
containing caffeine and from smoking for $24 h before studies.
A needle was inserted in the brachial artery of the nondomi-
nant arm that was slightly elevated above the level of the right
atrium, and a mercury-filled Silastic strain gauge was placed on
the widest part of the forearm. The strain gauge was connected
to a plethysmograph (model EC-4, D. E. Hokanson, Issaquah,
Washington) calibrated to measure the percent change in
volume; the plethysmograph in turn was connected to a chart
recorder to record the forearm flow measurements. For each
measurement, a cuff placed on the upper arm was inflated to
40 mm Hg with a rapid cuff inflator (model E-10, Hokanson) to
occlude venous outflow from the extremity. A wrist cuff was
inflated to suprasystolic pressures 1 min before each measure-
ment to exclude hand circulation. Flow measurements were
recorded for approximately 7 s every 15 s; 7 readings were
obtained for each mean value.
Basal measurements were obtained during intraarterial
infusion of 5% dextrose solution at 1 ml/min. Forearm flows
were then measured after the infusion of intraarterial ACH at
30 and 60 mg/min. Each dose was infused for 5 min and
forearm flow was measured during the last 2 min of the
infusion. Measurements were repeated 20 min after intrave-
nous L-arginine or D-arginine on both days.
Plasma arginine, insulin, prolactin and glucose measure-
ments. Before the study and after 20-min infusions of L- and
D-arginine, blood sampling was performed in 10 patients to
measure serum glucose, prolactin, insulin and arginine levels.
Statistical analysis. Data are expressed as mean 6 SEM.
The difference between means was tested with paired or
unpaired Student’s t test as appropriate. All tests were two-
sided and a p , 0.05 was considered statistically significant.
The hemodynamic changes during exercise and the dose
response curves with ACH before and after L- and D-arginine
were compared using a two-way repeated measures analysis of
variance (ANOVA) (23) with appropriate interaction terms.
Results
Effects of intravenous D- and L-arginine on endothelial
function. Figure 1 demonstrates the effect of both arginine
enantiomers on forearm vascular endothelial function. Fore-
arm vasodilation occurred with both intravenous L- and D-
arginine; compared to baseline, forearm blood flow increased
by 33% 6 6% with L-arginine and 38% 6 7% with D-arginine,
and forearm vascular resistance decreased by 28% 6 5% and
21% 6 5%, respectively (all p , 0.001). There was no
difference between the magnitude of vasodilation with D-
compared to L-arginine. Mean arterial pressure remained
unchanged with both drugs; 22% 6 1% (p 5 0.1) change with
L-arginine and 2% 6 1% (p 5 0.3) change with D-arginine.
Acetylcholine produced progressive forearm microvascular
dilation that was enhanced by both L-arginine (p , 0.0001,
ANOVA) and D-arginine (p , 0.0001, ANOVA) (Fig. 1);
thus, at the peak dose of ACH, forearm blood flow increased
from 17.4 6 2.2 ml/min/100 ml to 21.5 6 2.3 ml/min/100 ml
(p 5 0.01) with L-arginine and from 14.4 6 1.9 to 19.4 6 2.4
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ml/min/100 ml (p , 0.001) with D-arginine. Because of the
change in resting blood flow with L- and D-arginine, we also
calculated the flow increment, compared to baseline, with
ACH before and after arginine (Fig. 2). This analysis demon-
strated a significant further enhancement (above resting levels)
in ACH-induced vasodilation with both L- and D-arginine.
There was no change in arterial pressure during administration
of ACH either before or after L-arginine or D-arginine.
Effects of intravenous D- and L-arginine on exercise hemo-
dynamics. There was no alteration in heart rate, systolic,
diastolic or mean arterial pressures with either L-arginine or
D-arginine at rest (Fig. 3). During treadmill exercise there was
also no significant change in heart rate, systolic blood pressure
or rate-pressure product achieved at each stage during D5W,
L-arginine or D-arginine administration (Fig. 3). Peak exercise
duration remained unchanged, and the heart rate, blood
pressure and rate-pressure product achieved at peak exercise
were unchanged during D- and L-arginine therapy and D5W
administration (Fig. 4). Finally, there was no significant change
in the duration of exercise or heart rate and blood pressure at
1-mm ST-segment depression during L-arginine or D-arginine
therapy compared to control exercise with D5W.
Subgroup analysis. Previous studies have demonstrated
improvement in peripheral vascular endothelial function with
L-arginine in subjects with hypercholesterolemia and in those
with more severe coronary vascular endothelial dysfunction
(21,23). We therefore analyzed two subgroups, those with
more severe vascular endothelial dysfunction and patients with
hypercholesterolemia, to investigate whether arginine was of
greater benefit in these subsets.
Patients were divided into two equal-sized groups with
either “depressed” or “normal” endothelial function based on
that peak response to ACH. Both groups of patients had
improvement of ACH-mediated vasodilation with L- and
D-arginine (Fig. 5). During treadmill exercise testing, there
was no change in the ischemic threshold or hemodynamics at
peak exercise with L-arginine or D-arginine compared to D5W
in either patients with depressed or normal endothelial func-
tion (Fig. 5).
Finally, responses in patients with hypercholesterolemia
Figure 1. Forearm blood flow and
vascular resistance changes with
intraarterial ACH before and after
L- and D-arginine. p values repre-
sent two-way repeated measures
ANOVA.
Figure 2. Increase in forearm blood flow with
ACH during dextrose infusion (control) and after
L-arginine and D-arginine. The flow increment
beyond baseline changes observed with both ar-
ginine enantiomers is shown. p values represent
two-way repeated measures ANOVA.
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(total cholesterol .250 mg/dl, mean 293 6 10, n 5 11) were
compared to those with lower serum cholesterol levels (,250
mg/dl, mean 193 6 7, n 5 11). Both hypercholesterolemic and
normocholesterolemic patients had improvement of ACH-
mediated forearm vasodilation with L- and D-arginine, with no
difference in the magnitude of improvement between the two
arginine enantiomers in either subgroup (p 5 0.38 in normo-
cholesterolemic and p 5 0.34 in hypercholesterolemic patients,
D- vs. L-arginine). There was no change in the ischemic
threshold or hemodynamics at peak exercise with either
L-arginine or D-arginine compared to D5W either in patients
with or in patients without hypercholesterolemia.
Serum arginine, prolactin, glucose and insulin levels (Ta-
ble 1). Serum arginine level increased from 17.9 6 2 to 406 6
64 mmol/dl (p , 0.001) with L-arginine administration for
30 min and from 16.5 6 4 to 519 6 64 mmol/dl (p , 0.001) with
intravenous D-arginine. This was associated with a simulta-
neous increase in serum prolactin and insulin levels with both
L- and D-arginine. There was no significant difference between
the magnitude of increase in serum insulin (85% 6 22% vs.
108% 6 35%) or prolactin (207% 6 29% vs. 191% 6 49%)
with L-arginine or D-arginine, respectively. Glucose levels
remained unchanged during both infusions (Table 1).
Discussion
Our study demonstrates that both enantiomers of arginine,
when administered intravenously to patients with atheroscle-
rotic coronary artery disease, produce forearm vasodilation at
rest and enhance endothelium-dependent dilation in response
to ACH. Despite improvement of vascular function at rest and
with pharmacologic stimulation, there is no significant amelio-
ration of myocardial ischemia during exercise.
Arginine and endothelial function. Demonstration of en-
hanced NO production from the vasculature of hypercholes-
terolemic and atherosclerotic animals with endothelial dys-
function has been a stimulus for using L-arginine in human
studies (13,14). Peripheral arteriolar dilation in response to
Figure 3. Changes in heart rate, mean arterial blood
pressure and rate-pressure product during exercise with
intravenous dextrose 5% (D5W), L-arginine or
D-arginine. p values represent two way repeated measures
ANOVA.
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ACH improved with intraarterial L-arginine but not D-
arginine in normal subjects, but not in those with hypertension,
hypercholesterolemia or atherosclerosis (21,24–27). In con-
trast, intravenous L-arginine but not D-arginine improved
forearm dilation in hypercholesterolemic subjects in response
to methacholine (14). In the coronary vasculature, improve-
ment in ACH responses in hypercholesterolemic and athero-
sclerotic patients with intraarterial L-arginine could not be
reproduced with intraarterial D-arginine (16–18). Finally, oral
arginine also improved brachial artery flow-mediated dilation,
a surrogate measure of endothelial cell integrity in hypercho-
lesterolemic subjects, but not in normal individuals (28). Taken
together, these studies suggest that the route of administration
of arginine, the vascular bed and the specific causes leading to
endothelial dysfunction may, to some extent, influence the
response of arginine in vivo.
It is noteworthy that non–stereo-specific arteriolar and
venous dilation accompanied by hypotension occurs in normal
subjects at high parenteral concentrations of both L- and
D-arginine (29–31). We observed peripheral vasodilation at
somewhat lower concentration in patients with atherosclerosis
in whom blood pressure remained unchanged, suggesting that
either reflex constriction occurred in other vascular beds or
there was a simultaneous increase in cardiac output (30). Of
interest, heart rate also remained unchanged, indicating that
there was no systemic compensation for the mild peripheral
vasodilation observed with arginine. Surprisingly, both L- and
D-arginine produced enhancement of ACH-mediated forearm
vasodilation to a similar extent, a finding present in patients
throughout the range of responses to ACH. This contrasts with
previous observations where intravenous L-arginine but not
D-arginine improved methacholine responses in hypercholes-
terolemic patients (14). These differences might be explained
either because the serum arginine levels were lower than those
achieved in our study, or fewer patients were studied with
D-arginine or methacholine and not ACH was used as a probe
for testing endothelial function in that study.
Mechanisms underlying arginine-mediated improvement
in endothelial function. L-arginine but not D-arginine is a
substrate for NO synthesis. L-arginine is catalyzed by the
action of NO synthase to yield NO and L-citrulline (32). The
Km for L-arginine in normal endothelial cells (2.9 mmol/liter) is
several magnitudes lower than the intracellular concentrations
of L-arginine (0.8 to 2 mmol/liter), which makes it unlikely that
substrate deficiency is limiting for NO synthesis (33). Indeed,
in vitro, improvement with L-arginine can only be seen when
its levels are depleted (34). In contrast, parenteral arginine in
vivo increases vascular NO activity (29,30). Although it is
believed that endothelial dysfunction in hypercholesterolemia,
diabetes and atherosclerosis is due to inactivation of NO by
oxygen-free radicals, it is unlikely that substrate limitation
occurs even in these circumstances of increased NO turnover
(35). Furthermore, were this to be the mechanism, only
L-arginine but not D-arginine would be expected to produce
improvement of the ACH response.
There are several other proposed mechanisms whereby
L-arginine may improve endothelial function. These include:
1) reversal of inhibitory effects of L-glutamine on L-arginine
bioavailability (34), 2) counteracting the inhibitory effects of
asymmetric dimethyl arginine (ADMA), a naturally occurring
inhibitor of L-arginine (36–38), 3) its anti-oxidant actions
(38,39), 4) stimulation of insulin release (40–44) and 5)
nonenzymatic and non–stereo-specific generation of NO by
arginine (45).
Figure 4. The heart rate, mean ar-
terial blood pressure, rate-pressure
product and the duration of exercise
at 1-mm ST-segment depression
during treadmill exercise testing with
dextrose 5% (D5W), L-arginine and
D-arginine. There were no significant
differences between the treatments
by two-way repeated measures
ANOVA.
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Because it is clear that the actions of arginine in reversing
the inhibitory effects of L-glutamine, superoxide anions and
ADMA are all specific for the L-enantiomer, it is likely that
our observations of non–stereo-specific improvement in ACH
responses are either a result of hormonal stimulation, in
particular of insulin, or due to NO generation by the nonen-
zymatic pathway.
Myocardial ischemia and coronary artery disease. Myo-
cardial ischemia in patients with obstructive coronary artery
disease is believed to be primarily due to the myocardial
oxygen demand during exercise outstripping coronary blood
flow delivery across the atherosclerotic narrowing. However,
overwhelming evidence indicates that coronary vasomotion
importantly modifies the ease with which myocardial ischemia
occurs (1). Thus, increased coronary vascular tone can some-
times dramatically reduce coronary blood flow delivery, exac-
erbating myocardial ischemia. Vasoconstriction or failure of
normal vasodilation during physiologic stress of the coronary
vasculature in the presence of atherosclerosis and risk factors
for atherosclerosis, is believed to be secondary to the develop-
ment of endothelial dysfunction and reduced NO bioavailabil-
ity during stress (3–12).
Using L-NGmonomethyl arginine (L-NMMA), a specific
antagonist of NO synthesis, it was shown that the deficiency in
NO activity during stress accounted for the abnormal vasodi-
lation during atrial pacing of the coronary circulation and
during hyperemia in the peripheral circulation (24,46). Based
on these findings, we hypothesized that improvement of endo-
thelial NO activity with parenteral L-arginine, by abrogating
vasoconstriction during stress, will ameliorate myocardial isch-
emia. Other effects of arginine, including reduction in viscosity
and inhibition of platelet activation, may theoretically have
contributed to the beneficial effects that were anticipated
(29,47).
Despite producing baseline dilation and improving
endothelium-dependent responses, there was no improvement
Figure 5. The increase in forearm blood flow with L-arginine
and D-arginine compared to control in patients with initially
“depressed” endothelial function (n 5 11) is compared to
responses in patients with better (“normal”) endothelial
function (n 5 11). The rate-pressure product and duration of
exercise at 1-mm ST-segment depression during exercise is
also demonstrated. There was no significant difference be-
tween the groups by two-way repeated measures ANOVA.
(D5W 5 dextrose 5%.)
Table 1. Plasma Levels of Arginine, Prolactin, Insulin and Glucose
L-Arginine D-Arginine
Baseline Peak Baseline Peak
Arginine (mmol/dl) 17.9 6 2.4 406 6 64** 16.5 6 4 519 6 64**
Prolactin (mg/ml) 5.5 6 0.8 16 6 1.2** 6.0 6 1.2 16.2 6 2.9**
Insulin (mU/ml) 40 6 9 85 6 15.4** 27.1 6 6.9 51.6 6 12.3*
Glucose (mg/dl) 140 6 15 131 6 14 149 6 27 166 6 26
*p , 0.02; **p , 0.01.
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in the ischemic threshold or the peak exercise performance
with L-arginine or D-arginine. Furthermore, improved vascu-
lar tone at rest and with ACH did not affect blood pressure
changes with exercise during arginine compared to control
periods. Failure of improvement in myocardial ischemic
threshold when NO activity was likely enhanced (29,30) may
mean that vasomotor tone changes dependent on the endothe-
lial NO pathway are not playing an important role in precipi-
tation of exercise-induced myocardial ischemia. Alternatively,
it is possible that the sympathetic nervous system activation
associated with parenteral arginine infusion and precipitated
by increased insulin release (44,47) may counteract the positive
effects of increased NO availability on vasomotor tone. Also, it
is possible that arginine-mediated improvement of ACH re-
sponses does not translate into improved NO availability
during physical stress in the coronary vasculature. However,
this is unlikely because we have demonstrated improved
ACH-mediated and pacing-induced coronary vasodilation in
patients with atherosclerosis during local infusions of
L-arginine in the coronary vasculature (18).
Limitations. We have not measured the forearm vascular
responses to an endothelium-independent vasodilator to con-
firm whether the observed improvement with arginine was
specific for endothelial function and did not extend to the
vascular smooth muscle. However, many previous studies have
shown that neither L-arginine nor D-arginine improve sodium
nitroprusside responses (14,24). Because of the double-blind
nature of the study design, we were unable to test a range of
arginine dosages. We selected our infusion rate based on
previous studies demonstrating improvement of vascular
endothelial function with doses of L-arginine between 0.5
and 1.0 mg/kg/min.
Our findings cannot be extended to other subgroups of
patients with myocardial ischemia, such as variant angina,
Syndrome X or unstable angina, where both vasoconstriction
and platelet activation are major pathophysiologic etiologic
factors, and may not be applicable to spontaneous ischemic
episodes. Inhibition of platelet aggregation and coronary va-
sodilation with L-arginine could be of therapeutic benefit in
these conditions.
Conclusions. Our study demonstrates non–enantiomer-
specific improvement of peripheral vascular endothelial func-
tion with arginine, an effect that is likely to be due either to
stimulation of insulin-dependent NO release or by nonenzy-
matic NO generation by parenteral D- and L-arginine. Acute
administration of arginine did not improve myocardial isch-
emia during stress in patients with stable coronary artery
disease. Whether long-term oral therapy will achieve this goal
and whether parenteral arginine will be beneficial in other
acute ischemic syndromes needs to be explored further.
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